Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
doi: 10.1111/dom.14110 152 WillmsBWernerJHolstJJOrskovCCreutzfeldtWNauckMA
Treating these people with a synthetic GLP-1 supplement, they reasoned, could help restore a healthy insulin response and bring down blood glucose levels
Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides
Notably, a key feature of this approval is its link to the FDAs National Priority Voucher (CNPV) program
When budget sourcing makes sense: Non-critical applications, preliminary exploration, or highly price-sensitive research may justify budget vendor selection